Understanding D-Glyceric Aciduria

Receiving a diagnosis of D-Glyceric Aciduria (DGA) can feel like being handed a map to a place that hasn’t been fully explored. Because this condition is so rare, you may find that many doctors have never encountered it before. This page is designed to help you understand what is currently known about DGA and to validate the uncertainty you may be feeling as you navigate this diagnosis.

What is D-Glyceric Aciduria?

D-Glyceric Aciduria (DGA), also known as D-glyceric acidemia or glycerate kinase deficiency, is an extremely rare inherited metabolic disorder ^[1][2]. In a typical body, an enzyme called D-glycerate kinase acts directly on a substance called D-glycerate, which arises during the normal breakdown of certain protein components (serine) and sugars (fructose) ^[3].

In individuals with DGA, this enzyme does not work correctly, leading to an accumulation of D-glycerate ^[2]. This excess D-glycerate is filtered out by the kidneys and excreted in the urine, which is how the condition is often detected ^[1].

Understanding the Rarity

If you feel like you are searching for answers in a very small room, it is because DGA is exceptionally rare. A recent medical literature review indicates that only about 18 individuals globally have been tentatively diagnosed with the condition ^[4]. Older scientific reviews have listed smaller numbers, such as 7 or 15 cases ^[2][5]. These differing counts depend on the year of publication and how the researchers defined a “case” (e.g., biochemically suspected versus genetically confirmed).

Because there are so few cases, there is no “standard” experience. Every child identified with DGA adds a significant amount of information to what the world knows about this condition.

The Genetic Cause

DGA is a genetic condition usually caused by changes (variants) in the GLYCTK gene ^[5]. This gene provides the instructions for making the D-glycerate kinase enzyme.

DGA is an autosomal recessive disorder ^[5]. This means:

• A child must inherit two disease-causing (pathogenic) variants in the GLYCTK gene—one from each parent—to have the condition.
• The parents are typically “carriers,” meaning they have one changed copy and one healthy copy of the gene and usually do not show any symptoms themselves.
• When two carriers have a child, there is a 25% chance the child will inherit both changed genes ^[5].

A Wide Spectrum of Possibilities

One of the most challenging aspects of DGA for families is its clinical variability. This means that two individuals with similar genetic variants can have very different experiences ^[1].

The reported “spectrum” of DGA is broad:

• Asymptomatic: Some individuals are identified with DGA (often because a family member was tested) but never develop any health or developmental problems ^[4][2].
• Mild to Moderate: Some children may experience mild developmental or speech delays ^[6].
• Severe: In a few reported cases, children have faced significant neurological challenges, such as hypotonia (low muscle tone), seizures, microcephaly (a smaller-than-expected head size), or progressive encephalopathy (brain dysfunction that worsens over time) ^[3][4].

In one published case report, two siblings were found to have the exact same genetic variants and similar levels of D-glycerate in their urine ^[1]. One sibling had severe developmental challenges, while the other was healthy and developing normally ^[1].

Navigating the Uncertainty

Because of this wide range, doctors cannot predict how DGA will affect a specific child based solely on a lab test or a genetic report ^[1]. There is no known urine-level threshold that reliably predicts disease severity.

Medical researchers are still debating whether the D-glycerate kinase deficiency itself causes all these symptoms, or if some children have the deficiency while their severe symptoms are caused by an undiscovered, separate issue ^[2][4]. Because the condition is so rare, you and your medical team will likely focus on your child’s specific symptoms and developmental progress rather than a “textbook” version of the disease, which does not yet exist.